ATE468119T1 - Verfahren zur behandlung von krebs - Google Patents

Verfahren zur behandlung von krebs

Info

Publication number
ATE468119T1
ATE468119T1 AT07736446T AT07736446T ATE468119T1 AT E468119 T1 ATE468119 T1 AT E468119T1 AT 07736446 T AT07736446 T AT 07736446T AT 07736446 T AT07736446 T AT 07736446T AT E468119 T1 ATE468119 T1 AT E468119T1
Authority
AT
Austria
Prior art keywords
treating cancer
mammal
cancer
treating
oleandomycin
Prior art date
Application number
AT07736446T
Other languages
German (de)
English (en)
Inventor
Rina Rosin-Arbesfeld
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE468119T1 publication Critical patent/ATE468119T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT07736446T 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs ATE468119T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81260506P 2006-06-12 2006-06-12
PCT/IL2007/000706 WO2007144876A1 (en) 2006-06-12 2007-06-12 Methods for treating cancer

Publications (1)

Publication Number Publication Date
ATE468119T1 true ATE468119T1 (de) 2010-06-15

Family

ID=38541966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07736446T ATE468119T1 (de) 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs

Country Status (7)

Country Link
US (1) US9486467B2 (enExample)
EP (1) EP2029147B1 (enExample)
JP (1) JP2009539970A (enExample)
CN (1) CN101568343A (enExample)
AT (1) ATE468119T1 (enExample)
DE (1) DE602007006663D1 (enExample)
WO (1) WO2007144876A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102778A2 (en) 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2015198329A1 (en) 2014-06-25 2015-12-30 Bio Blast Pharma Ltd. Injectable formulations for intrathecal administration of antibiotic agents
EA037729B1 (ru) * 2017-02-22 2021-05-14 АйЭсАр ИММЬЮН СИСТЕМ РЕГЬЮЛЕЙШН ХОЛДИНГ АБ (ПАБЛ) Новый иммуностимулирующий макролид
WO2018184587A1 (zh) * 2017-04-06 2018-10-11 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
ES2912734T3 (es) * 2017-07-04 2022-05-27 Shenyang Fuyang Pharmaceutical Tech Co Ltd Uso de isovaleril espiramicina I o III en la preparación de fármaco para tratar y/o prevenir el tumor y fármaco
MX2020007625A (es) * 2018-01-19 2020-11-24 Shenyang Fuyang Pharmaceutical Tech Co Ltd Inhibidor mtor, composicion farmaceutica y su uso.
WO2019141256A1 (zh) 2018-01-19 2019-07-25 沈阳福洋医药科技有限公司 可利霉素或其活性成分的用途
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
JP2025500833A (ja) * 2021-12-14 2025-01-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんの処置のためのクラスター化変異

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH619267A5 (enExample) 1975-08-01 1980-09-15 Sanraku Ocean Co
GB1540397A (en) 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
US4064143A (en) 1976-12-10 1977-12-20 Pfizer Inc. Oleandomycin derivatives
US4205163A (en) 1977-11-08 1980-05-27 Sanraku-Ocean Co., Ltd. Tylosin derivatives
US4124755A (en) 1978-01-03 1978-11-07 Pfizer Inc. 11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
SE445739B (sv) 1978-09-14 1986-07-14 Toyo Jozo Kk 3", 4"-diacyltylosinderivat
US4429116A (en) 1982-12-27 1984-01-31 Pfizer Inc. Alkylated oleandomycin containing compounds
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5324720A (en) 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
CA2127578A1 (en) 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
ES2231877T3 (es) * 1996-07-08 2005-05-16 GALDERMA RESEARCH & DEVELOPMENT, S.N.C. Derivados de adamantillo inductores de apoptosis y su utilizacion como agentes anticancerigenos.
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
HRP980646B1 (en) 1998-12-30 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. Novel oleandomycin derivatives
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
OA11945A (en) 1999-05-24 2006-04-13 Pfizer Prod Inc 13-Methyl erythromycin derivatives.
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20050171032A1 (en) 2002-04-11 2005-08-04 Children's Medical Center Corporation Methods for the treatment of cancer
CN1562066A (zh) 2004-04-14 2005-01-12 山东鲁抗舍里乐药业有限公司 酒石酸泰乐菌素颗粒剂及其制备方法
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products

Also Published As

Publication number Publication date
CN101568343A (zh) 2009-10-28
EP2029147A1 (en) 2009-03-04
EP2029147B1 (en) 2010-05-19
WO2007144876A1 (en) 2007-12-21
US20110306571A1 (en) 2011-12-15
DE602007006663D1 (de) 2010-07-01
JP2009539970A (ja) 2009-11-19
US9486467B2 (en) 2016-11-08

Similar Documents

Publication Publication Date Title
ATE468119T1 (de) Verfahren zur behandlung von krebs
NO20200775A1 (no) Fremgangsmåter og sammensetninger for behandling av kreft
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
IL240405A (en) Pharmaceuticals containing 1-pd antagonist to treat infections and tumors
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
BRPI0715845A2 (pt) Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão
EP2132240A4 (en) COMPOSITIONS AND METHOD FOR TREATING A WATER BLOCKED DRILL OXIDE
EP2140103A4 (en) COMPOSITIONS AND METHOD FOR TREATING A WATER BLOCKED BOREOLE
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
MX2009001072A (es) Proceso de sintesis de macrolido.
CR10667A (es) Compositions and methods for diagnosing and treating cancer
AR071808A1 (es) Formulaciones orales de analogos de citidina, metodo de tratamiento, composicion farmaceutica y uso
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
UA98303C2 (ru) Способ синтеза макролидов
MY149028A (en) Nalmefene hydrochloride dihydrate
WO2007149782A3 (en) Selective inhibitors for transferases
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
CL2008001740A1 (es) Compuestos derivados de piperidinas sustituidas, inhibidores de la dna-girasa y/o topoisomerasa iv; procedimeinto para su preparacion; composiicon farmaceutica que comprende estos compustos y su uso en el tratamiento de una infeccion bacteriana.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
BRPI0913583A2 (pt) composto, composição farmacêutica, método para inibir dna girase bacteriana e/ou topoisomerase iv bacteriana, para produzir um efeito antibacteriano, e para tratar uma infecção bacteriana em um animal de sangue quente, e, uso de um composto
WO2007060627A3 (en) Use of macrolide derivatives for treating acne

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties